描述了顺式和反式-4-苄基和4-(3-甲氧基苄基)-2-甲氧基羰基-1-甲基哌啶的合成;参见下文。从这些化合物获得的氨基酸和氨基醇无法环化。已制备出顺式-2-苄基-4-乙氧基羰基-1-甲基哌啶,其氨基酸盐酸盐在160°C的多磷酸中环化,得到2,4,5,6,7-六氢-3-甲基-2, 6-methano-1 H -3-benzazonin-7-将其转化为几种衍生物。水解并环化通过两种途径获得的4-苄基-4-乙氧基羰基-1-甲基哌啶,得到N-甲基螺并[茚满-2,4'-哌啶] -1-酮,其也被转化为几种衍生物。
PROCTOR G. R.; SMITH F. J., J. CHEM. SOC. PERKIN TRANS., PART 1, 1981, NO 6, 1754-1762
作者:PROCTOR G. R.、 SMITH F. J.
DOI:——
日期:——
5-HT1F AGONISTS
申请人:ELI LILLY AND COMPANY
公开号:EP1153013B1
公开(公告)日:2007-10-31
US6777428B1
申请人:——
公开号:US6777428B1
公开(公告)日:2004-08-17
[EN] 5-HT1F AGONISTS<br/>[FR] AGONISTES 5-HT1F
申请人:LILLY CO ELI
公开号:WO2000047559A2
公开(公告)日:2000-08-17
The present invention relates to a compound of formula (I) and a process for making; or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT1F receptors and inhibiting neuronal protein extravasation in a mammal.
5-HT1f agonist
申请人:Eli Lilly and Company
公开号:US06777428B1
公开(公告)日:2004-08-17
The present invention relates to a compound of formula I and a process for making:
or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT1F receptors and inhibiting neuronal protein extravasation in a mammal.